Further, prospective, multicenter studies are necessary to confirm that new biomarkers are superior to PSA testing, in terms of specificity and potential capacity to select patients at a higher risk of developing aggressive PCa. The gene discussed is KLK3; the disease is posterior cortical atrophy.